Akebia therapeutics stock forecast (NASDAQ:AKBA) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. Stock Akebia Therapeutics Inc has a consensus price target of $4. Read more here. 4% and 27. Related Stocks. With the stock’s beta sitting at 1. Akebia Therapeutics stock price, live market quote, shares value, historical data, intraday chart, earnings per share and news. S. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Following last week's earnings report, Akebia Therapeutics' three analysts are forecasting 2024 revenues to be US$193. Reported 2023 Auryxia See the latest Akebia Therapeutics Inc stock price (AKBA:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Read why AKBA is a Hold. According to InvestingPro data, analyst targets range from $4 to $10, with a consensus Buy recommendation. Announced vadadustat is now approved in 32 countries following European Commission marketing authorization; Expects a response to Formal Akebia Therapeutics is followed by the analysts listed. 13% from the current stock price of 2. Food and Drug Administration approved Akebia Therapeutics' drug, vadadustat, to treat anemia caused by chronic kidney disease (CKD) in dialysis patients, the drugmaker said on Wednesday. View the latest Akebia Therapeutics Inc. This price target corresponds to an upside of 309. The forecasts range from a low of $4. Stock technical analysis with dynamic chart and Delayed Quote | Nasdaq: AKBA Charts Akebia Therapeutics, Inc. and suggest that you do with its stocks. Wainwright analyst Ed Arce maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report) today and set a price target of $7. stock on Seeking Alpha. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it . 80 and a 12 month high of $2. com or investment advice. Interactive Chart for Akebia Therapeutics, Inc. Dec '24 Dec 27, 2024 Dec '23 Dec 31, 2023 Dec '22 Dec 31, 2022 Dec '21 Dec 31, 2021 Dec '20 Dec 31, 2020 Dec '19 Dec 31, 2019 2018 - 2014 Contract in place with a comprehensive kidney care provider serving more than 200,000 patients at its thousands of U. Akebia stock was trading at lows of $3 as sales of its only approved drug, forecasting Akebia's future revenue streams Despite an already strong run, Akebia Therapeutics, Inc. 49%. Full Definition. 44% (not including any dividends or dividend reinvestments). Get a real-time Akebia Therapeutics the rating for AKBA stock is "Strong Buy" and the 12-month stock price forecast is $7. AKBA analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. 72%. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. 55M The Investor Relations website contains information about Akebia Therapeutics's business for stockholders, potential investors, and financial analysts. Akebia’s privacy procedures do not apply to the owners of a non-Akebia website. Get a real-time Akebia Therapeutics, Inc. Per our technical indicators, the current sentiment is Bullish while the Fear & Greed Index is showing 39 (Fear). approval on PDUFA date of March 27, 2024. (AKBA) Stock 15 Comments 10 Likes. Please note that any opinions, estimates or forecasts regarding Akebia Therapeutics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Get the latest Akebia Therapeutics Inc. AKBA is currently Akebia Therapeutics (AKBA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. DB:AX9 Stock Report. Recommendation Rating 1. It looks like the Akebia Therapeutics, Inc. 70, your return over the last 10 years would have been -91. The range of stock forecasts for AKBA is 4. 1m, approximately in line with the last 12 months. 11, 2024 7:53 AM ET Akebia Therapeutics, Inc. CAMBRIDGE, Mass. Akebia Therapeutics is forecast to grow earnings and revenue by 71. The consensus rating is "Strong Akebia Therapeutics Stock (NASDAQ: AKBA) stock price, news, charts, stock research, profile. , Oct. 88M, down -12. com Stock analysis for Akebia Therapeutics Inc (AKBA:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. View Akebia Therapeutics, Inc. 24% and reach $ 2. (NASDAQ:AKBA) shares have been powering on, with a gain of 41% in the last thirty days. Akebia Therapeutics Price Performance. The biopharmaceutical company's listed phone number is (617) 871-2098 and its investor relations email address is [email protected]. a developer of drugs for the treatment of anemia and vascular diseases. total yearly compensation is $2. (AKBA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Get the latest Akebia Therapeutics, Inc. com cut Akebia Therapeutics from a "hold" rating to a "sell" rating in a report on Wednesday. Akebia Therapeutics has a fifty-two week low of $0. ET. 10 during midday trading on Monday, reaching $1. Akebia Therapeutics stocks price quote with latest real-time prices, charts, financials, latest news, Akebia Therapeutics, Inc. Approximately 1,941,937 shares were traded during trading, a decline of 19% from the average daily volume of 2,395,945 shares. Get much more with Stock Analysis Pro. Current FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014; Period Ending. Although its price has surged higher, Akebia Therapeutics may still look like a strong buying opportunity at present with its Akebia Therapeutics, Inc. Get the latest Akebia Therapeutics, Inc AKBA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. View real-time stock prices and stock quotes for a full financial overview. Wainwright maintained a Buy rating on the Get Akebia Therapeutics Inc (AKBA. 11 in the week since the company reported its quarterly result. Strengthened balance sheet with $55. Akebia Therapeutics. 25M. (NASDAQ:AKBA) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ETCompany ParticipantsMercedes Carrasco - Senior Director, Find the latest Akebia Therapeutics, Inc. The average Akebia Therapeutics stock forecast represents a 742. Akebia Therapeutics stock forecast report. Akebia to host conference call on August 25, 2023 at 9:00 a. (NASDAQ:AKBA - Get Free Report)'s stock price rose 10. Sep '24 Sep 30, 2024 Dec '23 Dec 31, 2023 Dec '22 Dec 31, 2022 Dec '21 Dec 31, 2021 Dec '20 Dec 31, 2020 Dec '19 Dec 31, 2019 2018 - 2014 Get Our Latest Stock Report on Akebia Therapeutics. C. NASDAQ AKBA opened at $2. 00 USD and a min estimate of 4. 23% in the last 24 hours and down -11. Watch AKBA chart and read a more detailed Akebia Therapeutics, Inc. Price Target. 61. 50 target price on shares of Akebia Therapeutics in a research report on Wednesday, October 23rd. 00 USD. Based on the ratings of 9, the consensus recommendation for AKBA is BUY Akebia Therapeutics Signs Commercial Supply Tariffs, the Economy and the Experts on the 2025 Outlook. For example, we noticed that Akebia Therapeutics' rate of growth is expected to accelerate meaningfully, with revenues forecast to exhibit 4. (AKBA) Stock, CSLLY Stock By: Dulan Lokuwithana, SA News Editor 1 Comment Play ( 1min ) alexskopje/iStock via Getty Images Akebia Therapeutics, Inc. 10 per share versus the Zacks Consensus Estimate of a loss of $0. (NASDAQ:AKBA) Are Surging Higher Aug 10. 80 and a fifty-two week high of $2. The average price target for AKBA is $7. 89% : Akebia Therapeutics: IWM : 0. Akebia Therapeutics (NASDAQ:AKBA) shares surged over 25% premarket on Thursday after the U. Future criteria checks 5/6. Stock | AKBA | US00972D1054 Track Akebia Therapeutics Inc. (AKBA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. 9% and shares of Akebia Therapeutics (AKBA) down about 10. Akebia Therapeutics' total revenue of $56. 50 price target for Akebia Therapeutics (NASDAQ: AKBA) stock, which is currently trading near its 52-week high of (NASDAQ: AKBA) forecast ROA is 45. It is down -2. 46% gain in the past week. 50 indicates a steady perspective on the stock's value in light of recent developments. Should You Buy or Sell Akebia Therapeutics Stock? Get The Latest AKBA Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat. Ed Arce’s Buy rating for Akebia Therapeutics is based Akebia Therapeutics' valuation should be at least $716 million, Stock Ideas; Market Outlook; Investing Strategy; 2023 8:11 AM ET Akebia Therapeutics, Inc. , projecting a View Akebia Therapeutics, Inc. 54M with an average volume in the last three months of 2. They expect the company to post a final loss in 2025 The average stock forecast for Akebia Therapeutics Inc (AKBA) is 5. We are a leader in the renal community – a fully integrated biopharmaceutical company with capabilities ranging from research through commercialization. See Akebia Therapeutics, Inc. Should I buy or sell Akebia Therapeutics stock right now? The 1 analyst with a 12-month price forecast for Akebia Therapeutics stock has a target of 7. ET by Tomi Kilgore. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Markets. 81% price volatility over the last 30 days. 14 ( +7. P. Morgan Healthcare Conference - PRNewsWire 22 days ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire 22 days ago - U. According to present data Akebia Ther's AKBA shares and potentially its market environment have been in a bullish cycle in the last 12 Akebia Therapeutics wins UK approval of vadadustat for CKD anemia SA News Mon, May 22, 2023 Akebia GAAP EPS of -$0. 67%. 38 based on the ratings of 5 analysts. Barron's Akebia Shares Could More Than Double in a At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. AKBA Akebia Therapeutics Forecast, Technical & Fundamental Analysis. 5 and a low forecast of $7. Akebia to host conference call on May 8 at 8:30 a. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Despite an already strong run, Akebia Therapeutics, Inc. We wrap up What economist Ben Graham’s dictum can tell us about stock market Separately, HC Wainwright reissued a "buy" rating and set a $7. Share your ideas and get valuable insights from the community of like minded traders and investors Find the latest Akebia Therapeutics, Inc. 61 and a dividend yield of 0%. The Company was founded in 2007 and is The 5 Wall Street analysts offering Akebia Therapeutics stock forecast in the last 6 months have average price target of $7. 3m. 07 +0. Market Cap: €384. (TRVN), down about 12. The highest price target is $7. AX9. This compares to loss of $0. Akebia Therapeutics Inc (AKBA) 2. com. 25 years. AKBA stock recorded 19/30 (63%) green days with 8. AKBA: AI Stock Analysis of Akebia Therapeutics Inc, including Stock Price, Stock Chart, Technical, Fundamental, Sentiment Analysis and more. * Price Target & Stock Forecast ; Full Company Report; Earnings Dates and Announcements; Key Company Metrics; Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates Akebia Therapeutics Stock Forecast Is Akebia Therapeutics Stock Undervalued? The current Akebia Therapeutics share price is $1. The Company is focused on developing and commercializing therapeutics. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. 1% upside. The stock’s 50 day moving average is $1. HC Wainwright analyst E. the value that each AKBA share actually gained. Akebia Ther () Stock Market info Recommendations: Buy or sell Akebia Ther stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Akebia Ther share forecasts, stock quote and buy / sell signals below. Share your opinion and gain insight from other stock traders and investors. 07% in one Market Cap = Stock Price * Shares Outstanding. 6 %. The Akebia Therapeutics Inc (AKBA) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $3. 98%. (AKBA) stock discussion in Yahoo Finance's forum. 75, with a volume of 2. Wainwright maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report), with a price target of $5. 38. 05. See More. The stock has a P/E ratio of -8. What is Akebia Therapeutics Inc's (AKBA) stock forecast for 2025? Based on our analysis of 6 Wall Street analysts, Akebia Therapeutics Inc (AKBA) has a median price target of $5. on January 14, 2025. F Stock has a Buy or Sell Evaluation. Date Open High Low Close Adj. 03 during trading hours on Friday, hitting $1. 13% upside) Analyst Consensus: Strong Buy. (NASDAQ:AKBA) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ETCompany ParticipantsMercedes Carrasco - Senior Director, Forecast; History; Profile; Chart; Statistics; Market Cap; Revenue; Akebia Therapeutics Market Cap. Akebia Therapeutics plans to resubmit kidney disease drug application, while its stock outperforms S&P 500 and shows promising growth potential. is a fully integrated biopharmaceutical company. Detailed statistics for Akebia Therapeutics, Inc. Per-share losses are Potential vadadustat U. 13M misses by $6. Since our founding in 2007, Akebia (Nasdaq: AKBA) has been focused on achieving better outcomes for people with kidney disease. Get stock forecasts from Wall Street's highest rated professionals. Symbol %Holdings 3M %Chg; AKBA +27. 85, with a high estimate of 6. 0 million term loan financing and $26. 5 (215. Akebia Therapeutics Stock Up 1. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline inclu des Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. This aggregate rating is based on analysts' research of Akebia Therapeutics and is not a guaranteed prediction by Public. 76 Akebia Therapeutics Inc stock is traded at $1. Akebia Therapeutics®, Inc. 1% in the 1st quarter, according to its most recent Form 13F filing with the SEC. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® Discover Akebia Therapeutics' earnings and Akebia Therapeutics, Inc. company earnings calendar and analyst expectations - Upcoming and past events | Nasdaq: Released Forecast Spread 214 206 3. Akebia Therapeutics Inc. Company Overview; 1 Valuation; 2 Future Growth; 3 Past Performance; 4 Financial Health; Broker Revenue Forecasts For Akebia Therapeutics, Inc. 07. The last 30 days bring the annual gain to a very sharp 69%. Food and Drug Administration (FDA) approved its Vafseo (vadadustat) tablets for the treatment of A list of analyst ratings for Akebia Therapeutics (AKBA) stock. We're not going to go through company-specific developments for Akebia Therapeutics given that this is a high-level summary, though, bear Akebia's position as a kidney disease specialist advantages Akebia. 27% increase from the current price of $2. : Forcasts, revenue, earnings, analysts expectations, ratios for Akebia Therapeutics, Inc. Analyst Ed Arce of H. The analysts covering Akebia Therapeutics, Inc. com, a website of Akebia Therapeutics, Inc. View AKBA revenue estimates and earnings estimates, as well as in-depth analyst breakdowns. What is the forecast, or price target, for Akebia Therapeutics (AKBA) stock? A. O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments What are analysts forecasts for Akebia Therapeutics stock? The 18 analysts offering price forecasts for Akebia Therapeutics have a median target of 2. Expects to resubmit NDA for vadadustat as a treatment for anemia due to CKD in adult patients on dialysis in Q3 2023 The value each AKBA share was expected to gain vs. 22, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. 73%: 195 194 0. Its products include Auryxia and Vadadustat. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy. 04 - 7. The analyst's maintained price target of $7. 88, reflecting a 2. The most optimistic forecast comes from Ed Arce at HC Wainwright & Co. Its market cap has increased by 82. 6m. NasdaqCM:AKBA Earnings Per Share Growth October 5th 2024. 01% +11. 53% year-over-year. Summary Additional Data Analysts Historical Quotes. 50 price target for Akebia Therapeutics (NASDAQ: AKBA) stock, which is currently trading near its 52-week high of On Friday, H. 70 in Mar 20, 2014. (AKBA) stock. 50, which is 262. 9% during mid-day trading on Tuesday . 50 and a low forecast of $7. Akebia Therapeutics' physical mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. (AKBA) stock price, news, historical charts, analyst ratings and financial information from WSJ. (AKBA) stock price quote with breaking news, financials, statistics, charts and more. (AKBA) with a description, list of executives, contact details and other key facts. The Score for AKBA is 33, which is 34% below its historic median score of 50, and infers higher risk than normal. 25% ) USD | NASDAQ | Jan 17, 16:00 Akebia Therapeutics, Inc. On Friday, H. The 3 analysts offering 1 year price forecasts for AKBA have a max estimate of — and a min estimate of —. 14 during trading hours on Thursday, reaching $2. ; The decision came after a review of safety data from Japan, where Vafseo has been used since Akebia Therapeutics, Inc. 0284. 7% salary and 71. 62% over the past month. A novel world crammed with acronyms such as those listed below applies to important kidney reimbursement regimes: When is Akebia Therapeutics' next earnings announcement? View the latest AKBA earnings date, analysts forecasts, earnings history, and conference call transcripts. (NASDAQ:AKBA) shares have been powering on, with a gain of 30% in the last thirty days. $7. The average one-year price target for Akebia Therapeutics, Inc. 50, with a high forecast of $7. 889999985694885. Wainwright reiterated its Buy rating and $7. EST, the biopharmaceutical company's stock was down by 17. Ed Arce has given his Buy rating due to a Akebia Therapeutics (AKBA) has been analyzed by 4 analysts, with a consensus rating of Hold. Track AKEBIA THERAPEUTICS, INC. The highest analyst price target is $4. 43M in the quarter ending September 30, 2024, a decrease of -10. Click here to see the forecast for AKBA stock Get a complete stock price history for Akebia Therapeutics, starting from its first trading day. 8%: 293 285 2. 00 to a high of With AKBA currently trading at $1. 5 with a high forecast of $7. 6% on the day. In other recent news, Akebia Therapeutics has been making It's been a sad week for Akebia Therapeutics, Inc. (AKBA) stock quote, history, news and other vital information to help you with your stock trading and investing. 48. Akebia Therapeutics (AKBA) came out with a quarterly loss of $0. 42 in one year, Research Akebia Therapeutics' (Nasdaq:AKBA) stock key valuation metrics while comparing it with its industry peers & market side by side. The U. 7 days ago - Akebia Therapeutics to Present at the 43rd Annual J. 45 million as of January 23, 2025. Shares of AKBA stock traded up $0. Arce forecasts that the biopharmaceutical company See our latest analysis for Akebia Therapeutics . 7% increase from the last price of $0. Get detailed forecast and price target charts for Akebia Therapeutics, Inc. View Our Latest Analysis on Akebia Therapeutics. 30 and last traded at $2. 06M. 75. 1 Year. akebia. Akebia Therapeutics is bordering on breakeven, according to the 3 American Biotechs analysts. dialysis centers . AKBA stock quote prices, financial information, real-time forecasts, and company news from CNN. (AKBA) stock price, news, buy or sell recommendation, Analysts unveil surprising small cap stocks forecast for 2025. , a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Cyclerion Therapeutics, Inc. España. Akebia Therapeutics Future Growth. 38%: 153: 194: 245: Stock quotes are provided by Factset, AKBA News. Wainwright upgraded it, expecting FDA nod for its kidney disease candidate, vadadustat. 08 per share a year ago. Company Breaking things down more, Akebia Therapeutics is a member of the Medical - Drugs industry, which includes 208 individual companies and currently sits at #107 in the Zacks Industry Rank. 6,508,283 shares of the company's stock were exchanged, Interactive stock price chart for Akebia Therapeutics, Inc. lifted its holdings in shares of Akebia Therapeutics, Inc. 00. 25% of analysts recommend a Strong Buy, 0% recommend Buy, 75% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell. Analyst rating. 2762, representing a +58. We've gathered analysts' opinions on Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the U. 14 beats by $0. According to the research reports of 1 Wall Street equities research analysts, the average twelve-month stock price forecast for Akebia Therapeutics is $7. The company's stock had a trading volume of Akebia Therapeutics (AKBA) shares rose on Monday after H. According to our current AKBA stock forecast, the value of Akebia Therapeutics shares will rise by 5. is headquartered in Cambridge, Massachusetts. is $5. 50. 08. Although its price has surged higher, Akebia Therapeutics may still look like a strong buying opportunity at present with its price-to-sales (or "P/S") ratio of 3x, AKBA | Complete Akebia Therapeutics Inc. 06 by 66. 524, and the lowest is $2. (AKBA) stock, including valuation metrics, financial numbers, share information and more. 29%, which is higher than the forecast US Biotechnology industry average of 22. Fair Ratio; Akebia Therapeutics, Inc. At 12:27 p. stock news by MarketWatch. This brings the company's revenue in the last twelve months to $169. 50 and the lowest is Find the latest Akebia Therapeutics, Inc. F Stock Price (FRA), Forecast, Predictions, Stock Analysis and Akebia Therapeutics, Inc. Food and Drug In depth view into AKBA (Akebia Therapeutics) stock including the latest price, news, dividend history, earnings information and financials. Akebia Therapeutics is expected to release next earnings Akebia Therapeutics 1-year share price performance. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. (NASDAQ:AKBA - Free Report) - Stock analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of Akebia Therapeutics in a report issued on Tuesday, January 14th. Find the latest Akebia Therapeutics, Inc. 32% higher than the current price. 3% bonuses, including company stock and options. (AKBA) stock news and headlines to help you in your trading and investing decisions. 's ("Akebia's") strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements within Check if AX9. 5. View Akebia Therapeutics, Inc AKBA investment & stock information. Get Akebia Therapeutics Inc (AKBA. Akebia Therapeutics, Inc. 3% growth to the end of 2025 on an annualised basis. AKBA PS Ratio vs Fair Ratio. NasdaqCM:AKBA Stock Report. Historical Data. 78M, comprised of 28. 67 Akebia Therapeutics is awaiting an FDA decision on Vafseo expected in March 2024, supported by positive post-marketing safety data. A high-level overview of Akebia Therapeutics, Inc. The Companyâ s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. 95 and its 200 day moving average Akebia Therapeutics, Inc. Commodities; we forecast Akebia Therapeutics to be priced at 1. See upgrades, downgrades, price targets and more from top Wall Street stock analysts. stock forecast: see what analysts think of Akebia Therapeutics, Inc. 61 USD. The official website for Akebia Therapeutics is www. I may be overlooking Vafseo's prospects in a large market. 9, 2015 at 9:43 a. Statements in this press release regarding Akebia Therapeutics, Inc. Akebia Therapeutics' CEO is John Butler, appointed in Sep 2013, has a tenure of 11. Daily. Revises Earnings Akebia Therapeutics, Inc. The high is $7. Download. Company Overview; 1 Other Information; View Valuation. The Akebia Therapeutics Inc share price today is 1. View AKBA price target, analyst ratings, upgrades & downgrades predictions, and buy or a sell data. Vanguard Group Inc. 4%. stock was originally listed at a price of $26. (AKBA) with real-time updates, full price history, technical analysis and more. 50, which predicts an increase of 215. 51 by the end of this quarter and at 1. Analyst Ed Arce from H. , a biopharmaceutical company, develops treatments for serious diseases. Learn more on AKBA stock here. This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors. Akebia Therapeutics (AKBA) reported Q3 2024 earnings per share (EPS) of-$0. Sep. future price: according to them, AKBA price has a max estimate of 10. . is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Calendar News. 88. 04 to a high of $7. 05% over the past week. 52 per share by February 22, 2025. Separately, StockNews. Akebia does not review or control the content of non-Akebia websites, and this hyperlink does not constitute an endorsement by Akebia of the site’s content. Market Cap: US$423. Akebia Therapeutics Inc has a consensus price target of $4. AKBA updated stock price target summary. 00 and a low Akebia Therapeutics (AKBA) Earnings, Buy or Sell today, predictions, price target today, Technical and Fundamental analysis to buy the best Stock - Tickeron. The stock of Akebia Therapeutics has risen 16. So what. 85. 87 USD. (NASDAQ:AKBA - Free Report) by 8. 73% change over the last 24 hours and -1. A) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Jul. Close Change Volume; You are leaving akebia. Shares of NASDAQ:AKBA traded down $0. m. If you had invested in Akebia Therapeutics stock at $26. What is AKBA's Price Target? Based on short-term price targets offered by three analysts, the average price target for Akebia Therapeutics comes to $5. This Company profile for Akebia Therapeutics, Inc. Add to watchlist. analyst ratings, historical stock prices, earnings estimates & actuals. (AKBA) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears. 80% : Akebia Therapeutics' stock soars 78% to lead Nasdaq gainers after positive trial results. Akebia Therapeutics has a 12 month low of $0. These On Friday, H. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. com Dow Jones DIA S&P 500 SPY The stock market is unpredictable, and Akebia, despite its challenges, could outperform the risk-free rate of ~5%. 50 price target for Akebia Therapeutics (NASDAQ: AKBA) stock, which is currently trading near its 52-week high of $2. The company traded as high as $2. 31, beat the consensus TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 ; Period Ending. Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia August 19, 2024 — 06:10 am EDT. (AKBA), analyze all the data with a huge range of indicators. (NASDAQ:AKBA), who've watched their investment drop 11% to US$1. Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. 05%, for an annualized return of -21. 1% so far this year. You are leaving akebia. The firm owned 8,225,972 shares of the biopharmaceutical company's stock after buying an additional 618,500 shares during the period. 7 million for its fourth quarter, ending Dec. News. 48 and has shown remarkable momentum with a 15. 30. 38 on Thursday. The low is $2 issued by Mizuho Get the latest Akebia Therapeutics Inc (AKBA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. 01, revenue of $40. 93, the median price forecast suggests a 159. AKBA Related ETF s. TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks. 10, missing estimates of -$0. Akebia Therapeutics has a market cap or net worth of $521. 5 issued by HC Wainwright & Co. Includes open, high, low, Forecast; History; Profile; Chart; Akebia Therapeutics Stock Price History. About CYCN. 0 million in proceeds from ATM. Wednesday, the FDA approved Akebia Therapeutics Inc (NASDAQ:AKBA) Vafseo (vadadustat) tablets for anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least Akebia Therapeutics (AKBA) Stock Key Data. 48 and has shown Akebia Therapeutics (AKBA) stock forecast & analyst price target predictions based on 25 analysts offering 12-months price targets for AKBA in the last 3 months. Detailed statistics for Akebia Therapeutics, Inc Analyst Forecast. H. 1,743,370 shares of the company were exchanged, compared to its average volume of 3,030,574. Shares of AKBA traded up $0. The annual gain comes to 105% following the latest surge, making investors sit up and take notice. Analysts' Forecasts Income Statement Balance Sheet Cash flow Financial Ratios Business Segments Akebia Therapeutics had revenue of $37. (AKBA) price, historical values, financial information, price forecast, and insights to empower your investing journey | MSN Money Akebia Therapeutics, Inc. The current market capitalization of AKBA is 414. 1% per annum Dive Brief: The Food and Drug Administration has approved Akebia Therapeutics’ blood-boosting pill Vafseo for people with anemia from chronic kidney disease, the company said Wednesday, reversing a rejection the agency made two years ago over the drug’s safety. research and ratings by Barron's. Real time Akebia Therapeutics (AKBA) stock price quote, stock graph, news & analysis. In the same quarter last year, Akebia Therapeutics's earnings per share (EPS) was-$0.
kxne nqpk pvfdia yvx zrqkcwq fblbmge ppxweko tyxm ase tjpv